drugset / Trial / NCT00519727

Safety Study of ISIS 325568 in Healthy Volunteers

NCT00519727 ↗

Phase 1 Completed 60 enrolled Ionis Pharmaceuticals, Inc.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The primary purpose of this trial is to assess the safety of ISIS 325568 when given at increasing single doses and to assess the safety of the same doses when given multiple times.

Timeline

Start
2007-08
Primary completion
2008-04
Completion
2008-06

Drugs

EvaluationDrugModalityDoseRoute
Subject ISIS 325568 Unknown 50 mg Subcutaneous
Subject ISIS 325568 Unknown 100 mg Subcutaneous
Subject ISIS 325568 Unknown 200 mg Subcutaneous
Subject ISIS 325568 Unknown 400 mg Subcutaneous